India Pharma Outlook Team | Friday, 04 July 2025
In an aim to expand in the high-value complex generics, Indian pharma major Lupin has introduced Ipratropium Bromide Nasal Solution to the United States. The product is the 0.03 percent and 0.06 percent generic equivalent of Atrovent Nasal Spray, which is used in the treatment of rhinorrhoea (runny nose) caused by allergy, common cold or non-allergic.
This is an announcement that will consolidate Lupin presence in the American generic market, especially the increasing complex generics segment which is more difficult to manufacture, needs sophisticated technology, and has higher margins. The firm has stated that the spray is bioequivalent to the reference drug, indicating that the spray has the same safety and efficacy levels as the one that it was compared against.
“This launch aligns with our ambition to expand our complex generics footprint in the U.S. and Europe,” Lupin said in its statement. According to earlier reports, Lupin is actively pursuing over 200 products in its pipeline and expects complex generics to contribute 62% of its revenue by FY30. By FY26, their contribution is projected to rise to 21%.
Complex generics such as inhalers, ophthalmic solutions, injectables, and transdermal patches require advanced delivery systems and bring significant value to manufacturers due to limited competition. Lupin’s latest move is a signal of its intent to lead this transformation.
With increasing healthcare demand and generic drug adoption in the U.S., Lupin’s latest nasal spray addition reinforces its competitive position while catering to unmet clinical needs in respiratory care.